Clinicians at the University of Nebraska have pioneered a first-of-its-kind treatment for multiple sclerosis (MS) using an off-the-shelf allogeneic CAR T-cell therapy, azercabtagene zapreleucel (azer-cel). This therapy is designed to target overactive immune cells in the central nervous system implicated in MS-driven neurodegeneration. Early trial participants have reported significant clinical improvements, including enhanced gait and better overall function. Progressive MS represents an unmet medical need due to the limited efficacy of current therapies within the central nervous system. This Phase I clinical trial, sponsored by TG Therapeutics, offers hope for durable control of disease progression through cellular immunotherapy.